select a format

Single User License
USD 250 INR 16045
Site License
USD 500 INR 32090
Corporate User License
USD 750 INR 48135

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Lonza Group Ltd (LONN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Lonza Group Ltd (LONN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH31043D
  • |
  • Pages: 71
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B compounds, industrial preservatives, microbial control solutions and organic personal care ingredients. It also provides custom development and custom manufacturing services to its clients. Lonza's client base includes professionals in the biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; distributors; formulators and service companies. The company's key markets include bioresearch, nutrition, pharma and biotech, microbial control, agriculture, materials science and personal care industries. It operates several manufacturing and research and development (R&D) facilities across Asia, Europe and Americas. Lonza is headquartered in Basel, Switzerland.

Lonza Group Ltd (LONN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10

Lonza Group Ltd, Medical Devices Deals, 2011 to YTD 2017 11

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 15

Venture Financing 16

Odyssey Thera Raises US$3 Million In Venture Financing 16

Private Equity 17

Kainos Capital Acquires InterHealth Nutraceuticals 17

Partnerships 18

BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 18

Lonza Enters into Agreement with Kodiak Sciences 19

Lonza Partners with Octane Biotech 19

Lonza and AMYRA Biotech Enter into Agreement 20

CSIRO Enters Into Co-Development Agreement With Lonza 20

Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 21

Lonza Enters Into Co-Marketing Agreement With Lipogen For Phosphatidylserine-Based Formulas 22

Shanghai Fosun Enters Into Joint Venture Agreement With Lonza Group 23

Athera Biotechnologies Enters Into Co-Development Agreement With Lonza 24

Licensing Agreements 25

Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 25

CytoDyn Enters into Licensing Agreement with Lonza Sales 26

Lonza Enters into Licensing Agreement with arGEN-X 27

Xbiotech Enters into Licensing Agreement with Lonza Sales 28

Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 28

Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 30

Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 30

Pierre Fabre Enters into Licensing Agreement with Lonza 32

Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 32

Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 33

Pierre Fabre Enters into Licensing Agreement with Lonza 34

Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 35

Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 36

Oxford BioTherapeutics Enters Into Licensing Agreement With Lonza 37

Enzymicals Enters Into Licensing Agreement With Lonza For (R)-selective Transaminases 38

Lonza Enters Into License Agreement With ORGANOBALANCE 38

Equity Offering 39

Lonza Raise USD2.24 Billion in Rights Offering of Shares 39

Lonza Raises USD871 Million in Private Placement of Shares 40

Lonza Group Completes IPO Of Common Stock On Singapore Exchange 41

Debt Offering 42

Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 42

Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 43

Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 44

Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 45

Lonza Completes Public Offering Of Bonds Due 2015 For US$266 Million 46

Lonza Completes Public Offering Of Bonds Due 2018 For US$155 Million 47

Asset Transactions 48

PolyPeptide to Acquire Peptides Business and Operations in Braine, Belgium from Lonza 48

Acquisition 49

Lonza to Acquire Capsugel from KKR & Co for USD5.5 Billion 49

Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 50

Lonza May Acquire Catalent 51

Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 52

Lonza Group Ltd-Key Competitors 54

Key Employees 55

Locations And Subsidiaries 56

Head Office 56

Other Locations & Subsidiaries 56

Recent Developments 60

Strategy And Business Planning 60

Feb 02, 2016: Lonza to Build Capabilities for Drug Product Development Services, Enabling One-Stop-Shop Solutions for Customers 60

Financial Announcements 61

Jan 25, 2017: Lonza Reports Record-Breaking Financial Performance, Resulting in 24.2% CORE EBIT Growth, Driven by Pharma and Biotech 61

Apr 26, 2016: Lonza Reports Record First Quarter 63

Jan 27, 2016: Lonza Reports Strong Sales and Profit Growth in 2015 64

Corporate Communications 66

Jan 25, 2017: Lonza Appoints Fridtjof Helemann, CHRO, to Executive Committee 66

May 10, 2016: Rodolfo Savitzky appointed as new CFO for Lonza to succeed Toralf Haag who was appointed as CFO of the Voith in Germany 67

Product News 68

Sep 07, 2016: Lonza Releases Second-Generation Immunogenicity Assessment and Optimization Platform for Development of Therapeutic Proteins, Vaccines and Cell Therapies 68

Mar 30, 2016: Lonza Launches Sentinel APART Server-Based Platform Designed to Help Improve the Quality and Safety of Therapeutic Antibodies 69

Other Significant Developments 70

May 17, 2016: Lonza CytoSMART Lab Free-Trial Initiative Launched 70

Appendix 71

Methodology 71

About GlobalData 71

Contact Us 71

Disclaimer 71

List of Figures

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10

Lonza Group Ltd, Medical Devices Deals, 2011 to YTD 2017 11

List of Tables

Lonza Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

Lonza Group Ltd, Deals By Therapy Area, 2011 to YTD 2017 10

Lonza Group Ltd, Medical Devices Deals, 2011 to YTD 2017 11

Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 15

Odyssey Thera Raises US$3 Million In Venture Financing 16

Kainos Capital Acquires InterHealth Nutraceuticals 17

BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 18

Lonza Enters into Agreement with Kodiak Sciences 19

Lonza Partners with Octane Biotech 19

Lonza and AMYRA Biotech Enter into Agreement 20

CSIRO Enters Into Co-Development Agreement With Lonza 20

Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 21

Lonza Enters Into Co-Marketing Agreement With Lipogen For Phosphatidylserine-Based Formulas 22

Shanghai Fosun Enters Into Joint Venture Agreement With Lonza Group 23

Athera Biotechnologies Enters Into Co-Development Agreement With Lonza 24

Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 25

CytoDyn Enters into Licensing Agreement with Lonza Sales 26

Lonza Enters into Licensing Agreement with arGEN-X 27

Xbiotech Enters into Licensing Agreement with Lonza Sales 28

Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 28

Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 30

Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 30

Pierre Fabre Enters into Licensing Agreement with Lonza 32

Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 32

Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 33

Pierre Fabre Enters into Licensing Agreement with Lonza 34

Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 35

Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 36

Oxford BioTherapeutics Enters Into Licensing Agreement With Lonza 37

Enzymicals Enters Into Licensing Agreement With Lonza For (R)-selective Transaminases 38

Lonza Enters Into License Agreement With ORGANOBALANCE 38

Lonza Raise USD2.24 Billion in Rights Offering of Shares 39

Lonza Raises USD871 Million in Private Placement of Shares 40

Lonza Group Completes IPO Of Common Stock On Singapore Exchange 41

Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 42

Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 43

Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 44

Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 45

Lonza Completes Public Offering Of Bonds Due 2015 For US$266 Million 46

Lonza Completes Public Offering Of Bonds Due 2018 For US$155 Million 47

PolyPeptide to Acquire Peptides Business and Operations in Braine, Belgium from Lonza 48

Lonza to Acquire Capsugel from KKR & Co for USD5.5 Billion 49

Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 50

Lonza May Acquire Catalent 51

Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 52

Lonza Group Ltd, Key Competitors 54

Lonza Group Ltd, Key Employees 55

Lonza Group Ltd, Subsidiaries 56

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Lonza Group Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com